Lattice Biologics closed a private placement for gross proceeds of up to US $0.75MM to fund M&A and the acquisition of donors to support production of an amniotic fluid product for regenerative use. The novel regenerative therapeutic will target osteoarthritis, spine, sports-medicine, foot/ankle and other indications. 

Contact Us

0